Jan 11, 2023 / 06:30PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Teva this morning. From the company, we have the company's recently appointed CEO, Richard Francis; as well as CFO, Eli Kalif. Eli is going to make an initial presentation then we're going to move over to some Q&A with both Richard and with Eli. So with that, welcome and look forward to the presentation.
Eliyahu Sharon Kalif - Teva Pharmaceutical Industries Limited - Executive VP & CFO
Thank you, Chris. Welcome, everyone. And just before I start, I want to thank Chris and JPMorgan team to have us presenting here. It's really nice to come back and now after 3 years, really more exciting.
So today, we're going to review a few elements. We're going to talk about Teva today, and we're going to elaborate on how we are progressing with our current financial targets. We shift around the debt. And then also, I will elaborate more about what we communicated in the third -- in
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers